335 related articles for article (PubMed ID: 22594889)
1. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
Bellail AC; Hao C
Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
[No Abstract] [Full Text] [Related]
2. The TRAIL apoptotic pathway in cancer onset, progression and therapy.
Johnstone RW; Frew AJ; Smyth MJ
Nat Rev Cancer; 2008 Oct; 8(10):782-98. PubMed ID: 18813321
[TBL] [Abstract][Full Text] [Related]
3. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
4. Is TRAIL the holy grail of cancer therapy?
Newsom-Davis T; Prieske S; Walczak H
Apoptosis; 2009 Apr; 14(4):607-23. PubMed ID: 19194800
[TBL] [Abstract][Full Text] [Related]
5. TRAIL receptor signaling and therapeutics.
Abdulghani J; El-Deiry WS
Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
[TBL] [Abstract][Full Text] [Related]
6. Role of elevated pressure in TRAIL-induced apoptosis in human lung carcinoma cells.
Oh S; Kwon D; Lee HJ; Kim J; Lee E
Apoptosis; 2010 Dec; 15(12):1517-28. PubMed ID: 20623193
[TBL] [Abstract][Full Text] [Related]
7. TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells.
Heijink DM; Jalving M; Oosterhuis D; Sloots IA; Koster R; Hollema H; Kleibeuker JH; Koornstra JJ; de Vries EG; de Jong S
J Pathol; 2011 Feb; 223(3):378-89. PubMed ID: 21171083
[TBL] [Abstract][Full Text] [Related]
8. [Recent advances for research on anti-tumor effects of TNF-related apoptosis-inducing ligand].
Yao GH; Hou YY
Wei Sheng Yan Jiu; 2006 Jan; 35(1):115-7. PubMed ID: 16598953
[TBL] [Abstract][Full Text] [Related]
9. TRAIL and cancer therapy.
Kruyt FA
Cancer Lett; 2008 May; 263(1):14-25. PubMed ID: 18329793
[TBL] [Abstract][Full Text] [Related]
10. From biochemical principles of apoptosis induction by TRAIL to application in tumour therapy.
Cordier SM; Papenfuss K; Walczak H
Results Probl Cell Differ; 2009; 49():115-43. PubMed ID: 19142621
[TBL] [Abstract][Full Text] [Related]
11. Spatial dynamics of TRAIL death receptors in cancer cells.
Twomey JD; Kim SR; Zhao L; Bozza WP; Zhang B
Drug Resist Updat; 2015 Mar; 19():13-21. PubMed ID: 25840763
[TBL] [Abstract][Full Text] [Related]
12. Developing TRAIL/TRAIL death receptor-based cancer therapies.
Yuan X; Gajan A; Chu Q; Xiong H; Wu K; Wu GS
Cancer Metastasis Rev; 2018 Dec; 37(4):733-748. PubMed ID: 29541897
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of CD95 and the TRAIL death receptors.
Gerspach J; Pfizenmaier K; Wajant H
Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):294-310. PubMed ID: 21762072
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis.
Peuhu E; Rivero-Müller A; Stykki H; Torvaldson E; Holmbom T; Eklund P; Unkila M; Sjöholm R; Eriksson JE
Oncogene; 2010 Feb; 29(6):898-908. PubMed ID: 19935713
[TBL] [Abstract][Full Text] [Related]
15. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
Cretney E; Takeda K; Smyth MJ
Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
[TBL] [Abstract][Full Text] [Related]
16. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
17. The TRAIL of oncogenes to apoptosis.
Oikonomou E; Pintzas A
Biofactors; 2013; 39(4):343-54. PubMed ID: 23813857
[TBL] [Abstract][Full Text] [Related]
18. TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule.
Manzo F; Nebbioso A; Miceli M; Conte M; De Bellis F; Carafa V; Franci G; Tambaro FP; Altucci L
Int J Biochem Cell Biol; 2009 Mar; 41(3):460-6. PubMed ID: 18243765
[TBL] [Abstract][Full Text] [Related]
19. IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells.
Büneker CK; Yu R; Deedigan L; Mohr A; Zwacka RM
Cancer Lett; 2012 Mar; 316(2):168-77. PubMed ID: 22104728
[TBL] [Abstract][Full Text] [Related]
20. TRAIL/TRAIL-R in hematologic malignancies.
Testa U
J Cell Biochem; 2010 May; 110(1):21-34. PubMed ID: 20336667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
